

Astrom Biosciences (ASTM): a regenerative medicine company focused on the clinical development of autologous (*from the patient's own body*) cell products for the repair or regeneration of multiple human tissues, based on proprietary "Tissue Repair Cell (TRC) Technology. Preclinical and clinical product development programs are under way utilizing patient-derived bone marrow stem and early progenitor cell (like embryonic stem cells in the sense that progenitors have the capacity for self-renewal and differentiation, the difference being that progenitor cells may be limited in their ability to do either) populations being investigated for their ability to aid in the regeneration of tissues such as bone, vascular, cardiac and neural.